Pulmonx Co. (NASDAQ:LUNG) CEO Sells $197,699.46 in Stock

Pulmonx Co. (NASDAQ:LUNG) CEO Steven S. Williamson sold 27,689 shares of Pulmonx stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.14, for a total value of $197,699.46. Following the completion of the transaction, the chief executive officer now owns 194,342 shares in the company, valued at approximately $1,387,601.88. This represents a 12.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pulmonx Stock Performance

Shares of LUNG stock opened at $7.48 on Friday. The business’s 50-day moving average price is $6.95 and its 200-day moving average price is $6.94. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $297.67 million, a price-to-earnings ratio of -5.19 and a beta of 0.50. Pulmonx Co. has a 12 month low of $5.46 and a 12 month high of $10.01.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The business had revenue of $23.77 million for the quarter, compared to analysts’ expectations of $22.29 million. Equities research analysts forecast that Pulmonx Co. will post -1.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wells Fargo & Company cut their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Citigroup reissued a “neutral” rating and set a $7.50 price target (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.75.

Institutional Trading of Pulmonx

Several institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in Pulmonx by 1.8% in the third quarter. Barclays PLC now owns 94,109 shares of the company’s stock valued at $780,000 after acquiring an additional 1,679 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Pulmonx by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock valued at $2,142,000 after acquiring an additional 2,363 shares during the last quarter. Rhumbline Advisers boosted its holdings in Pulmonx by 4.9% in the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock valued at $363,000 after acquiring an additional 2,488 shares during the last quarter. American Century Companies Inc. boosted its holdings in Pulmonx by 8.8% in the fourth quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock valued at $236,000 after acquiring an additional 2,810 shares during the last quarter. Finally, 272 Capital LP bought a new stake in Pulmonx in the third quarter valued at approximately $25,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.